| Drug Name |
MIDODRINE HCL |
| Active Ingredient(s) |
•MIDODRINE HYDROCHLORIDE |
Form(s) and
Strength(s) Available |
• TABLET; ORAL:2.5MG ;5MG |
Product Information / Press Release Midodrine, a prodrug, is converted to an active metabolite--desglymidodrine--that is an alpha-1 agonist. Desglymidodrine produces an increase in vascular tone and elevation of BP by activating alpha-adrenergic receptors of the arteriolar and venous vasculature. No effect on cardiac beta-adrenergic receptors. The active metabolite does not cross the blood-brain barrier; thus, there are no CNS effects. Standing systolic BP is increased by approximately 15-30 mm Hg at 1 hr after a 10-mg dose; duration: 2-3 hr. Rapidly absorbed from the GI tract. Peak plasma levels, midodrine: 30 min; t1/2: 25 min. Peak plasma levels, desglymidodrine: 1-2hr; t1/2: 3-4 hr. The bioavailability of the active metabolite is not affected by food. Desglymidodrine is eliminated in the urine.
Uses: Orthostatic hypotension in those whose lives are significantly impaired despite standard clinical care. Investigational: Management of urinary incontinence.
Contraindications: Use in severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma, thyrotoxicosis, persistent and excessive supine hypertension.
Special Concerns: Use with caution in impaired renal or hepatic function, during lactation, in orthostatic hypotensive clients who are also diabetic, or in those with a history of visual problems or who are also taking fludrocortisone acetate. Safety and efficacy have not been determined in children.
Manufacturers URL : www.eonlabs.com
|
|
Tell a friend about this item!